Experience with repetitive use of pimecrolimus: Exploring the effective and safe use in the treatment of relapsing seborrheic dermatitis

Journal of Dermatological Treatment

Volumn 21, Issue 2, 2010, Pages 83-85

  Tatlican, Semih ^a   Eren, Cemile ^a   Oktay, Bilgen ^a   Eskioglu, Fatma ^a   Durmazlar, Pelin Kartal ^a  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Pimecrolimus; Retreatment; Seborrheic dermatitis

Indexed keywords

PIMECROLIMUS;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CREAM; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE; REMISSION; RISK BENEFIT ANALYSIS; SEBORRHEIC DERMATITIS; SKIN EXAMINATION; SKIN TINGLING;

EID: 76749104192     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630902882055     Document Type: Article

References (17)

1. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2004;18:13-16.
2. Gupta AK, Medzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology. 2004;208:89-93.
3. Rigopoulos D, Ionnides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis: A randomized open-label clinical trial. Br J Dermatol. 2004;151:1071-1075.
4. Rallis E, Nasiopoulou A, Kouskoukis C, Koumantaki E. Pimecrolimus cream 1% can be an effective treatment of seborrheic dermatitis of the face and trunk. Drugs Exp Clin Res. 2004;30:191-195.
5. High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in african american adults with associated hypopigmentation. J Am Acad Dermatol. 2006;54:1083-1088.
6. Firooz A, Solhpour AM, Gorouhi F, Daneshpazhooh M, Balighi K, Farsinejad K, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: A randomized, investigator-blind, Clinical trial. Arch Dermatol. 2006;142:1066-1067.
7. Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007;57:257-264.
8. De Moraes AP, de Arruda EA, Vitoriano MAV, de moraes Filho MO, Bezerra FA, de magalhaes holanda E, et al. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrheic dermatitis infected with hIV. J Eur Acad Dermatol Venereol. 2007;21:596-601.
9. Kim BS, Kim SH, Kim MB, Oh CK, Jang HS, Kwon KS. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients. J Korean Med Sci. 2007;22:868-872.
10. Koc E, Arca E, Kose O, Akar A. An open, Randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 2009;20:4-9.
11. Tatlican S, Eren C, Eskioglu F. Insight into pimecrolimus experience in seborrheic dermatitis:Close follow-up with exact mean cure and remission times and side effect profile. J Dermatolog Treat. 2009;20:198-202.
12. Fritsch PO, Reider N. Other eczematous eruptions. eds, Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. Philadelphia: Mosby; 2003. 215-226.
13. Gupta AK, Nicol K, Batra R. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol. 2004;5:417-422.
14. Takeda K, Arase S, Takahashi S. Side effects of topical corticos-teroids and their prevention. Drugs.1988;36(suppl 5):15-23.
15. Watanabe S, Kano R, Sato H, Nakamura Y, Hasegawa A. The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol. 2001;116:769-773.
16. Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: Atopic dermatitis and beyond. Int J Clin Pract. 2005;59:969-974.
17. Sugita T, Tajima M, Tsubuku H, Tsuboi R, Nishikawa A. A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. Antimicrob agents chemother. 2006;50:2897-2898.